USV Launches INSUQUICK, First Biosimilar Insulin Aspart in India

USV Pvt. Ltd, leaders in oral anti-diabetes segment, has announced the launch of 1st biosimilar Insulin Aspart in India, INSUQUICK, for the treatment of people living with Diabetes

INSUQUICK^® is DCGI-approved for the management of glycemic control in people living with Diabetes.

INSUQUICK^® is available in INSUQUICK^® Cartridge, INSUQUICK^® vial & INSUQUICK^® VDPen.

INSUQUICK^® VDPen is a prefilled, disposable variable dose pen injector, featuring a modern robust design, lightweight, large legible scale, and with audible clicks for precise incremental settings.

USV has also announced the launch of USVPen^®, a reusable pen designed for USV’s range of insulin. USVPen^® delivers accurate dose of insulin with low dose force which makes it user-friendly.

Achieved through relentless R&D efforts of more than 10 years, INSUQUICK^® uses 100% indigenous robust technology, guaranteeing complete cold chain care. INSUQUICK^® aligns with global regulatory standards, making it a world-class and truly "Made in India" affordable solution.

Insuquick establishes fingerprint-like similarity in efficacy, safety, and immunogenicity profile as compared to Innovator.